Unknown

Dataset Information

0

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.


ABSTRACT: Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy. Enhanced clinical outcome using this approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, and/or additional cytokine support. However, the need for prior conditioning precludes optimal application of this approach to a significant number of cancer patients intolerant to these regimens. Herein, we present preclinical studies demonstrating that treatment with CD19-specific, chimeric antigen receptor (CAR)-modified T cells that are further modified to constitutively secrete IL-12 are able to safely eradicate established disease in the absence of prior conditioning. We demonstrate in a novel syngeneic tumor model that tumor elimination requires both CD4(+) and CD8(+) T-cell subsets, autocrine IL-12 stimulation, and subsequent IFN? secretion by the CAR(+) T cells. Importantly, IL-12-secreting, tumor-targeted T cells acquire intrinsic resistance to T regulatory cell-mediated inhibition. Based on these preclinical data, we anticipate that adoptive therapy using CAR-targeted T cells modified to secrete IL-12 will obviate or reduce the need for potentially hazardous conditioning regimens to achieve optimal antitumor responses in cancer patients.

SUBMITTER: Pegram HJ 

PROVIDER: S-EPMC3359735 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.

Pegram Hollie J HJ   Lee James C JC   Hayman Erik G EG   Imperato Gavin H GH   Tedder Thomas F TF   Sadelain Michel M   Brentjens Renier J RJ  

Blood 20120221 18


Adoptive cell therapy with tumor-targeted T cells is a promising approach to cancer therapy. Enhanced clinical outcome using this approach requires conditioning regimens with total body irradiation, lymphodepleting chemotherapy, and/or additional cytokine support. However, the need for prior conditioning precludes optimal application of this approach to a significant number of cancer patients intolerant to these regimens. Herein, we present preclinical studies demonstrating that treatment with C  ...[more]

Similar Datasets

| S-EPMC4404840 | biostudies-literature
| S-EPMC10074049 | biostudies-literature
| S-EPMC11292205 | biostudies-literature
| S-EPMC8386348 | biostudies-literature
| S-EPMC10475122 | biostudies-literature
| S-EPMC6362534 | biostudies-literature
| S-EPMC4807400 | biostudies-other
| S-EPMC5645350 | biostudies-literature
| S-EPMC3302816 | biostudies-literature
| S-EPMC5772011 | biostudies-literature